Alzheimer's Drugs Benefits Labeled 'Trivial'

The findings have provoked a fierce backlash from some dementia experts and pharmaceutical firms who argue that the review unfairly groups failed drugs with newer, approved treatments.

While the drugs successfully remove amyloid plaques from the brain, the study suggests this does not translate into noticeable improvements in daily function for patients.

The report comes as a blow to families who had hoped these 'wonder drugs' would mark the beginning of the end for the disease.

Regulatory bodies in the UK and US are now facing calls to re-evaluate the cost-effectiveness of these expensive therapies.